Key result
Novel prehospital GP IIb/IIIa inhibitor zalunfiban enters phase 3 testing for STEMI.
Why the study?
Zalunfiban is a novel glycoprotein IIb/IIIa inhibitor being evaluated for prehospital antiplatelet use in STEMI patients with limited current knowledge.
Does zalunfiban provide safe and effective antiplatelet effects in the prehospital setting for patients with ST-elevation myocardial infarction?
Does zalunfiban provide safe and effective antiplatelet effects in the prehospital setting for patients with ST-elevation myocardial infarction?
Zalunfiban is a novel glycoprotein IIb/IIIa inhibitor that shows promise for prehospital antiplatelet therapy in STEMI patients.
Answers are grounded in this paper and cite their sources.
Zalunfiban shows early safety for prehospital STEMI antiplatelet therapy; leaves open phase 3 efficacy before clinical adoption.
Zalunfiban is a novel glycoprotein IIb/IIIa inhibitor currently being tested for its use in the prehospital setting for antiplatelet effect in patients with ST-elevation myocardial infarction. It has shown to be safe and effective in both phase 1 and phase 2 trials and is under investigation in phase 3 trials. In this review, we discuss zalunfiban in detail, including its mechanism of action, adverse effects, current recommendations for use, and ongoing trials.
No takes yet. Share an insight, caveat, or question.
Veasaw et al. (2024) conducted a review in ST-elevation myocardial infarction. Zalunfiban was evaluated. Zalunfiban is a novel glycoprotein IIb/IIIa inhibitor under investigation for prehospital use in patients with ST-elevation myocardial infarction, with ongoing phase 3 trials.
Synapse has enriched 10 related papers. Consider them for comparative context: